GnRH analogues and uterine leiomyomas. Effect of hormone replacement therapy on cell proliferation.
Cell proliferation in uterine leiomyomas treated preoperatively with either nafarelin (400 microg/day) for 3 months (7 patients) or nafarelin plus hormone (oestradiol + norethisterone) add-back therapy (6 patients) was investigated by automatic image analysis of frozen tissue sections using immunohistochemistry with anti-proliferating cell nuclear antigen antibody. GnRHa therapy decreased cell proliferation in leiomyomas to a level corresponding to the situation previously seen in postmenopausal leiomyomas. However, there was no consistent correlation between cell proliferation and shrinkage of leiomyomal size. The hormone add-back therapy moderated the influence of GnRHa on cell proliferation and completely blocked a decrease in size of leiomyomas in our patients.
Rintala
S
S
Department of Anaesthesiology and Intensive Care, Tampere University Hospital, Tampere, Finland.
Kujansuu
E
E
Teisala
K
K
Rantala
I
I
Kivinen
S
S
Tuimala
R
R
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002455:Cell Division; D004958:Estradiol / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D017273:Goserelin / Q000008:administration & dosage / Q000627:therapeutic use; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D007044:Hysterectomy; D007889:Leiomyoma / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D008875:Middle Aged; D017274:Nafarelin / Q000008:administration & dosage / Q000627:therapeutic use*; D009640:Norethindrone / Q000008:administration & dosage / Q000627:therapeutic use; D011292:Premedication; D011300:Preoperative Care; D014594:Uterine Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*
D000970:Antineoplastic Agents; D006728:Hormones; D017273:Goserelin; D017274:Nafarelin; D004958:Estradiol; D009640:Norethindrone